NCT02281383View on ClinicalTrials.gov

Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

February 24, 2022

Study Completion Date

February 24, 2022

Conditions

Bladder CancerHigh Risk Superficial

Interventions

BIOLOGICAL

Bacillus Calmette-Guérin (BCG)

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Commack, Commack

Unknown

Memorial Sloan Kettering Cancer Center, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02281383 - Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer | Biotech Hunter | Biotech Hunter